Du et al. demonstrated that the serum CA-125 levels of PTB patients with type 2 DM (82.04 ± 82.96 U/ml) are significantly higher than those of PTB patients without DM (46.56 ± 42.47 U/ml) in initial treatment; moreover, the serum CA-125 levels of pulmonary adenocarcinoma patients (287.95 ± 341.64 U/ml) were also significantly higher than those of PTB patients with type 2 DM in initial treatment and retreatment, PTB patients without type 2 DM in initial treatment and retreatment, inactive PTB, bacterial pneumonia patients, patients with type 2 DM without PTB, and normal controls [7]. The gene discussed is MUC16; the disease is bacterial pneumonia.